REPURPOSING, REPOSITIONING AND RESCUE OF DRUGS AND PHARMACEUTICALS
Senior Patent Attorney, Dr Lisa Brown explores repurposing, repositioning and rescue (DRPx) of existing drugs and pharmaceuticals.
Ideas lead to innovation and innovation distinguishes those companies that lead from those that follow
TLIP Ltd – leading European Patent & Trade Mark Attorneys and Portfolio Management Support
Global Reach
Our clients’ commercial interests extend across the world. To support those interests, TLIP has appointed a network of approved overseas associate firms with expert local knowledge. We work together to provide you with a truly international service.
Unitary Patent System – Updates
Liam Lawlor summaries the legal status of the European Unitary Patent System as it stands today.
JUNE UPDATE: Coronavirus pandemic advice from patent offices
UKIPO and EPO provide updates on extensions of time due to the coronavirus outbreak.
Repurposing, Repositioning and Rescue of Drugs and Pharmaceuticals
Following on from our News Article of 6 April 2020 “Personalised Medicine Patents at the EPO”, regarding a case law summary of the patent protection available for existing pharmaceuticals in terms of dosing regimens and specific patient groups, we now look to explore repurposing, repositioning and rescue (DRPx) of existing drugs and pharmaceuticals.
Our Expertise
TLIP attorneys work in specialist technology and legal fields. Our attorneys include an astrophysicist, a synthetic chemist, an IBM patent engineer, an electronic engineer, a mechanical engineer and a toxicologist. Whilst we are mostly known for our original patent drafting and patent prosecution, we also advise our clients across all IP rights: including trade secrets, contracts and licensing. We combine this with a good dose of real life experience and learning from clients that continually push the boundaries of what is possible.